Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Immuno-Oncology 2022 | Modulating the tumor microenvironment to enhance cancer vaccines

Michael Nishimura • 28 Nov 2022
ESMO Immuno-Oncology 2022
General Antibodies Checkpoint Inhibitors

Lymphodepletion with chemotherapy is typically carried out before administering cell therapies to ensure the cells can proliferate. Michael Nishimura, PhD, Loyola University Chicago, Chicago, IL, discusses strategies to boost the efficacy of cancer vaccines. Whilst lymphodepletion can suppress the activity of immune cells such as regulatory T cells (Tregs) and myeloid-derived suppressor cells, immune checkpoint inhibitors may be more suitable to complement the activity of vaccines. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michael Nishimura

2:37
What does the future hold for cellular therapies in solid tumors?
Michael Nishimura • 28 Nov 2022
2:31
Addressing and overcoming limitations in cancer vaccines
Michael Nishimura • 28 Nov 2022

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals